Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Summary

This phase I/II trial studies the side effects and best dose of lenalidomide and pidilizumab and to see how well they work in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as pidilizumab, can block cancer growth by blocking the ability of cancer to grow and spread. Giving lenalidomide with pidilizumab may work better in treating relapsed or refractory multiple myeloma.

Timeline

Start

2014-03-03

Primary completion

2019-05-24

Completion

2019-05-24

Drugs

Indications